Objective: We aimed to investigate risk of hepatitis B virus reactivation in systemic lupus erythematosus patients with different hepatitis B virus infection statuses receiving immunosuppressive therapy. Methods: We retrospectively analyzed systemic lupus erythematosus patients with positive hepatitis B surface antigen or anti-hepatitis B core IgG antibody who underwent immunosuppressive therapies from January 2001 to December 2012 at a medical center in Taiwan for evidence of hepatitis B virus reactivation. Results: During this period, 906 out of 3125 patients who were diagnosed with systemic lupus erythematosus received screening tests for hepatitis B virus. Thirty-eight patients were identified as hepatitis B surface antigen-positive. Fifteen of 38 (39.5%) hepatitis B surface antigen-positive patients developed hepatitis B virus reactivation, and 53.3% of these patients experienced severe hepatitis flare. Three of 157 hepatitis B surface antigen-negative/anti-hepatitis B core IgG antibody-positive patients (1.9%) experienced hepatitis B surface antigen seroreversion after immunosuppressive therapy. Five patients received prophylactic or preemptive antiviral therapy and none of them developed hepatitis B virus flares. A daily dose of prednisolone greater than 5 mg was a risk factor for hepatitis B reactivation by multivariate logistic analysis. Conclusions: The risk of hepatitis B virus reactivation is high in lupus patients receiving immunosuppressive therapy. Antiviral prophylaxis or preemption can effectively reduce the incidence of hepatitis B virus reactivation in lupus patients. Lupus (2018) 27, 66-75.
Introduction
Hepatitis B virus (HBV) infection is a major health problem globally and an estimated 350 million people are chronically infected. 1 Taiwan is a highly endemic area of HBV infection. Before a universal HBV vaccination program was established in 1984, the HBV surface antigen (HBsAg) carrier rate was 15-20% and the anti-hepatitis B core IgG antibody (HBcAb) positive rate was 80-90%. 2, 3 Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by repeated flares and remission. 4 Persistent lupus activity or treatment-related complications may result in organ dysfunction over time. 5 The majority of lupus patients receive glucocorticoids, disease-modifying anti-rheumatic drugs (DMARDs) or biological therapy (e.g. rituximab) for treatment of disease flare and prevention of organ damage. 4, 5 Hepatitis B reactivation is caused by the replication of HBV and reappearance of active necroinFammatory liver disease in patients with inactive HBV carrier status or resolved hepatitis B. 1 The prevalence of HBV reactivation was 20% to 50% in HBV carriers undergoing immunosuppressive treatment or chemotherapy. 1 Emerging evidence demonstrates that HBV reactivation may occur both in chronic hepatitis B patients and occult HBV infection (negative HBsAg, positive HBcAb, and detectable serum HBV DNA) patients receiving immunosuppressive therapy or anti-tumor necrosis factor a (anti-TNF-a) therapy. [6] [7] [8] Reactivation of hepatitis B after chemotherapy or immunosuppressive therapy could lead to fulminant or fatal hepatitis with a high mortality rate. 9, 10 Fortunately, prophylactic or preemptive use of antiviral agents is an effective strategy to reduce mortality in patients treated with immunosuppressants. 8, 11 However, reports of HBV reactivation in SLE patients with positive HBsAg or HBcAb undergoing immunosuppressive therapy are scarce. In the present study, we investigated the risk of hepatitis B reactivation in SLE patients with different HBV infection statuses receiving immunosuppressive therapy.
Methods

Patients
We retrospectively reviewed the medical records of 3125 consecutive SLE patients who fulfilled the 1997 American College of Rheumatology revised classification criteria for SLE and had received a catastrophic illness certificate from the National Health Insurance of Taiwan from January 2001 to December 2012 at a medical center in Taiwan. 12 Taiwan's National Health Insurance program established a registry of patients with catastrophic illness, including 31 disease categories such as cancer, cirrhosis with refractory ascites or hepatic encephalopathy or variceal hemorrhage, end-stage renal disease, and SLE. The certification of catastrophic illness was further critically reviewed and confirmed by a second rheumatologist according to clinical manifestations, laboratory, image, and histological examinations.
Use of systemic glucocorticoids and immunosuppressants including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, cyclosporine, and rituximab was recorded. For patients with hepatitis B flare, the average daily glucocorticoid doses (prednisolone-equivalent doses) and types of immunosuppressants were calculated based on medications that were prescribed within three months before hepatitis B flare. For patients without hepatitis B flare, the average daily glucocorticoid doses were calculated for the whole follow-up period and types of immunosuppressants were medications that were prescribed in the follow-up period. The levels of anti-ds-DNA antibodies, C3, and C4 were recorded at the time of hepatitis B flares or at the end of the follow-up period.
The end-point of follow-up included mortality, development of hepatitis B flare, patient loss to follow-up, or 31 December 2015.
The study was approved by the Institutional Review Board and Independent Ethics Committee (IRB/IEC) of Taichung Veterans General Hospital, Taiwan. Because this study was a retrospective evaluation of hepatitis B viral reactivation in lupus patients using immunosuppressive agents, the IRB specifically waived the consent requirement.
Methods
Baseline characteristics, including age at diagnosis of SLE, gender, serial alanine aminotransferase (ALT), total bilirubin levels, and prothrombin time (PT) were collected. HBsAg, hepatitis B envelope antigen (HBeAg), hepatitis B envelope antibody (anti-HBe), HBcAb, and hepatitis B surface antibody (anti-HBs) were detected by electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). Serum levels of HBV DNA were determined by real-time polymerase chain reaction assay (Roche Diagnostics, Basel, Switzerland). Anti-ds-DNA antibodies and C4 levels were measured according to the manufacturer's instructions (Inova Diagnostics Inc., San Diego, USA, and Siemens, Munich, Germany, respectively).
Definition of HBV reactivation
Patients were categorized as having mild hepatitis B flare, severe acute exacerbation of HBV, hepatic decompensation and fulminant hepatic failure according to the clinical status and change of biological data after immunosuppressive therapy. Hepatitis B flare was defined by two independent hepatologists after excluding other liver diseases (e.g. hepatitis C, drug-induced liver injury, alcoholic hepatitis, non-alcoholic fatty liver disease, and autoimmune hepatitis). Mild hepatitis B flare was defined as a five-fold increase in ALT that exceeded the upper limit of normal (ULN, 44 U/ L) without hepatic decompensation. Severe acute exacerbation (SAE) of HBV was defined as more than a ten-fold elevation of ALT that exceeded the ULN or hepatic decompensation. 1, 13, 14 Hepatic decompensation was defined as jaundice (total bilirubin level >2 mg/dL), or more than a three-second prolongation of prothrombin time. 15 Fulminant hepatic failure was deEned as hepatic decompensation, presence of hepatic encephalopathy, and coagulopathy (prothrombin time exceeding 10 seconds of control). 9 HBsAg seroreversion was defined as reappearance of HBsAg in serum from previous seronegativity after immunosuppressive therapy.
Statistical analysis
The categorical variables are presented as numbers and percentages and were compared using chisquared test ( 2 test 
Results
Flowchart of enrolled SLE patients
In total, 3125 patients were diagnosed with SLE and 906 patients received HBV screening for either HBcAb or HBsAg (Figure 1 ). Thirty-eight patients were categorized as HBV carriers with positive HBsAg and negative anti-HBs. HBV acute flare was common in HBV carriers (15 of 38, 39.5%). Seven patients developed mild flares and eight patients experienced severe acute exacerbation, including five patients with hepatic decompensation (Table 1) . One of them developed fulminant hepatic failure and died. Positivity of HBcAb with negative HBsAg was found in 157 patients. Three of them (1.9%) experienced HBsAg seroreversion and two patients (1.3%) had severe HBV reactivation.
Demographic data and laboratory findings of enrolled SLE patients Table 1 shows the demographic data and laboratory findings of enrolled lupus patients. Age, gender, and baseline ALT were similar in HBsAg (þ), HBcAb (þ), and HBsAg seroreversion groups. HBsAg positivity rate was higher in male than in female lupus patients. The flare of ALT levels during HBV reactivation were significantly higher in the HBsAg seroreversion group than in the HBsAg (þ) group (p ¼ 0.037).
Characteristics of SLE patients with severe acute exacerbation of HBV Eight HBsAg (þ) patients and two HBcAb (þ) patients with HBsAg seroreversion had severe acute exacerbation of HBV during glucocorticoid and immunosuppressive therapy and all of them received rescue antiviral therapy (Table 2 ). Ten patients, including five males and five females, experienced severe acute exacerbation of HBV. Patient 1 and patient 2 were HBsAg seroreverters. Two patients died of fulminant hepatic failure despite the use of antiviral rescue therapy. One received an average daily dose of 18.75 mg of prednisolone-equivalent glucocorticoid and daily 75 mg cyclophosphamide in the three months before hepatitis B flare, while the other patient received 5 mg prednisolone and 50 mg azathioprine daily. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 16 scored from zero to 12 points in patients with severe acute exacerbation of hepatitis B. It appeared that HBV reactivation was not related to lupus disease activity. Eight patients recovered from severe HBV flares after treatment with oral antiviral agents. 
Clinical and laboratory characteristics of SLE patients with HBsAg seroreversion
Three patients (two females and one male) experienced HBsAg seroreversion. As shown in Table 3 , none of the seroreverters had detectable anti-hepatitis B core IgM antibody (anti-HBc IgM). The HBsAg seroreverter who died was previously seropositive for anti-HBs. Among three HBsAg seroreverters, one received preemptive lamivudine therapy due to HBV viremia (HBV DNA 5.63 Â 10 7 IU/mL). Follow-up HBV DNA level was undetectable 12 months later, even with continuing immunosuppressive therapy. Two HBsAg seroreverters received rescue antiviral treatment after severe ALT flares and hepatic decompensation. One of them died of fulminant hepatic failure despite timely antiviral therapy after severe HBV flare. Of note, patient 2 was the only patient among 41 HBV carriers (HBsAg-positives and HBsAg-seroreverters) born after 1984, the year that the universal hepatitis B vaccination program was implemented in Taiwan. She received a rituximab injection four months before hepatitis B flare (Table 3) .
Risk factors of hepatitis B flares
All 41 hepatitis B carriers (HBsAg-positives and HBsAg-seroreverters) received corticosteroids and immunosuppressive therapy for more than four consecutive weeks in the follow-up period. As shown in Table 4 , male gender and daily glucocorticoid treatment of >5 mg prednisolone-equivalent dose were risk factors for hepatitis B flare according to the results of the univariate logistic regression analysis. However, a daily dose of prednisolone >5 mg was the only independent predictor of hepatitis B flare in lupus patients by multivariate logistic regression analysis. To elucidate the effect of combined immunosuppressive therapy, we analyzed the risk of HBV flare associated with nine regimens of combination therapy using logistic regression analysis (Table 5 ). Using daily glucocorticoid more than 5 mg prednisolone-equivalent dose alone was associated with higher risk of HBV reactivation when compared with a smaller daily glucocorticoid dose alone or combined with other immunosuppressants.
Prophylaxis and preemption of anti-viral therapy
None of the seventeen patients with hepatitis B reactivation received prophylactic or preemptive antiviral therapy. In contrast, four HBsAg-positive patients and one HBsAg seroreverter underwent prophylactic or preemptive antiviral treatment ( Figure 1 ) and none of them experienced ALT flare. Although this result did not reach statistical significance (p ¼ 0.065) due to the small case number, there was a trend showing that antiviral prophylaxis or preemption may be effective in preventing HBV reactivation.
Discussion
Our data showed that 39.5% of HBsAg-positive SLE patients experienced HBV reactivation after treatment with immunosuppressants and corticosteroids. This prevalence rate was higher than that found in our previous report indicating that 27 .7% of rheumatoid arthritis (RA) patients experienced HBV reactivation after anti-TNF-a therapy and was higher than in another prospective study of the same ethnic group which showed 6.51% RA patients had HBV reactivation undergoing conventional DMARDs. 8, 17 Long-term corticosteroid therapy is the mainstay of treatment to suppress disease activity and prevent major organ damage for most lupus patients. 18 However, conventional and biological DMARDs were more important for treating RA than corticosteroids. 19, 20 Treatment with more corticosteroids may explain, at least in part, why the HBV reactivation rate was higher in lupus patients than in RA patients. However, further investigations are warranted.
Our study revealed that use of glucocorticoid greater than a daily 5 mg prednisolone-equivalent dose for more than four weeks had an increased hazard ratio of hepatitis B reactivation using multivariate logistic regression analysis. Previous studies showed that use of corticosteroids is a well-known risk factor of HBV reactivation in cancer therapy. [21] [22] [23] Patients with asthma or chronic obstructive pulmonary disease receiving low-dose systemic corticosteroids or even inhaled corticosteroids had increased risk of hepatitis B reactivation. 24 The guidelines of the American Gastroenterological Association (AGA) note that HBsAg-positive carriers receiving low-dose corticosteroids (prednisolone less than 10 mg daily or equivalent) or moderate-dose corticosteroids (prednisolone 10-20 mg daily or equivalent) for more than four weeks have a moderate to high risk of HBV reactivation. 25 These reports support our result that showed long-term low-dose corticosteroid, even as low as 5 mg daily prednisolone-equivalent dose, is a risk factor for hepatitis B reactivation. In our analysis of immunosuppressive agents, either alone or combined with corticosteroids, we found a non-significant increased risk of hepatitis B flare. Patients 1 and 10 in Table 2 received oral cyclophosphamide for lupus nephritis because oral cyclophosphamide had been shown to be beneficial for lupus nephritis in the 1990s. 26, 27 Although in the regression analysis cyclophosphamide was not associated with HBV flares, it should be avoided nowadays.
Our study showed that the HBV reactivation rate was high among HBsAg-positive and HBsAg seroreversion patients. Prevention of HBV flare in patients undergoing immunosuppressive therapy is important but challenging for physicians. Previous retrospective studies emphasized the use of HBV virologic monitoring, instead of serial ALT tests, and timely administration of antiviral agents upon diagnosis of HBV reactivation. 9, 28 Therapeutic antiviral therapy upon detection of HBV-related hepatitis Fares did not change the clinical course of HBV reactivation. 28 Early antiviral therapy is crucial to prevent severe acute hepatitis flares and hepatic failure in patients receiving immunosuppressive therapy. However, the high cost of the medication is a considerable financial burden for many patients. The median time of HBV reactivation after receiving immunosuppressive therapy was 69.47 (interquartile range, 34.64-102.73) months in all 17 patients with HBV reactivation. The duration of HBV reactivation after immunosuppressants may range from one to 8.5 years. Long-term close monitoring is necessary. Longterm, periodic monitoring of HBV viral load could be more effective at predicting imminent hepatitis flare under ideal circumstances. However, this may not be clinically practical in countries with limited resources. Thus, periodic monitoring of AST and ALT levels for detection of hepatitis flare may provide a more feasible option.
Universal screening for HBV serological markers, including HBsAg and HBcAb, are indicated in SLE patients before starting immunosuppressive therapies. 29 The AGA guidelines suggest that HBsAg-positive patients should receive prophylactic antiviral agents before administering immunosuppressants in high-risk groups. 25 For patients with seronegative HBsAg but seropositive HBcAb, HBV DNA or AST/ALT checkup before and periodically after immunosuppressive therapy are recommended. If HBsAg seroreversion is encountered, the risk of severe acute exacerbation is remarkably high. In this event, prompt administration of preemptive antiviral agents can effectively suppress HBV activity. For patients with risk of HBV reactivation but moderate-severe lupus, simultaneous immunosuppressive therapy and antiviral agents with high potency and a high genetic barrier to resistance (e.g. entecavir or tenofovir) are suggested. 25, 29 Since the risk of HBV reactivation remains probable even after eight years of immunosuppressive therapy, as shown in the present study, long-term antiviral therapy should be considered as long as immunosuppressants are used. 29 Based on our study results, previous studies, and current guidelines, we propose an algorithm ( Figure 2) for screening HBV and a strategy of prophylactic/preemptive antiviral therapy in lupus patients before scheduled immunosuppressive therapy. We emphasize the importance of screening for HBsAg and HBcAb before starting immunosuppressive therapy. For HBsAg-positive patients, it is recommended that HBV viral loads should be checked and preemptive/prophylactic antiviral treatment be prescribed before immunosuppressive therapy. For HBsAg-negative/HBcAb-positive patients, anti-HBs should be checked. If anti-HBs is negative, checking HBV DNA level is crucial. For patients with occult HBV infection (detectable DNA), preemptive therapy should be given. For patients with resolved HBV infection (undetectable DNA) or positive anti-HBs, even if the rate of HBV reactivation is relatively low, close monitoring of ALT levels is still recommended during the period of immunosuppressive therapy.
There are several limitations to this study. First, due to the retrospective study design, only 29.0% patients were screened for HBV. Some patients received the HBsAg test due to an abnormal liver function test after starting immunosuppressants. However, there might be some patients with inactive HBV infection with normal liver function test or asymptomatic hepatitis flares during the course of SLE treatment who did not receive the HBsAg test. Moreover, due to the limited number of cases, the statistical evidence was not robust. Greater emphasis should be placed on physicians' awareness of HBV screening. Further prospective studies are needed to confirm these findings. Second, not all patients with positive HBsAg or negative HBsAg/positive HBcAb had baseline HBV DNA data before immunosuppressive therapy. The definition of hepatitis B reactivation in this study was based on biochemical but not virologic evidence. However, two hepatologists reviewed the medical records and laboratory tests independently before categorizing HBV flares. Therefore, causes of ALT elevation other than HBV reactivation were excluded.
Conclusions
HBV reactivation was high in HBsAg-positive SLE patients undergoing immunosuppressive therapy. HBsAg seroreversion in HBcAb-positive SLE patients was not unusual and was often life-threatening due to HBV reactivation. Use of long-term prednisolone greater than 5 mg daily was a risk factor for hepatitis B reactivation. Antiviral prophylaxis or preemption may effectively reduce HBV reactivation in HBsAg-positive SLE patients.
